NICE’s Position on AI in Evidence Generation

By João L. Carapinha

November 18, 2024

The National Institute for Health and Care Excellence (NICE) has issued a position statement on the use of artificial intelligence (AI) in evidence generation. This statement clarifies what NICE expects when incorporating AI methods for evidence generation and reporting. The guidance emphasizes the necessity for transparency, rigor, and trust throughout the evidence generation process.

Key Objectives and Expectations

The position statement outlines NICE’s expectations regarding AI methods in evidence generation. It highlights the importance of adhering to existing regulations, good practices, and guidelines when utilizing AI methods.

Benefits of AI in Evidence Generation

AI methods, such as machine learning and generative AI, can efficiently handle large datasets, reveal patterns, and produce novel outputs beneficial for evidence synthesis. This capability can significantly enhance clinical evidence, trial design, systematic reviews, real-world data analysis, and cost-effectiveness studies.

Transparency and Justification

When AI is employed, it is essential for reporting to be transparent. NICE advises using established checklists like PALISADE to justify AI application and TRIPOD+AI to outline AI model development. Any AI approach must be treated as part of the clinical trial, with comprehensive details provided in the submission.

Human Involvement and Oversight

NICE emphasizes that AI should enhance human involvement, not replace it. Human oversight is vital to validate AI-generated outputs and to mitigate risks like algorithmic bias.

Specific Applications of AI

AI can streamline conventional literature search and review processes, covering search strategies, study classification, primary and full-text screening, and visualizing search results. Also, large language models (LLMs) can automate data extraction and generate code for synthesizing gathered data.

In real-world data analysis, AI supports various evidence generation stages, including updating economic models with newly acquired information.

Engagement with NICE

Organizations looking to leverage AI methods should engage with NICE to review their plans. Initial engagement can occur through NICE Advice, with further discussions involving the appropriate NICE technical teams taking place in later stages.

Future Considerations

NICE recognizes that other institutions, like Cochrane and the Guidelines International Network, are also developing guidelines for responsible AI use in evidence synthesis. This trend indicates greater integration of AI in health technology assessments (HTA).

In conclusion, NICE’s position on AI in evidence generation emphasizes its potential benefits while stressing the importance of transparency, human oversight, and strict adherence to existing standards and regulations to ensure the effectiveness and trustworthiness of AI methods.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.